ANI Pharmaceuticals, Inc. (ANIP), Monday announced the launch of Pimozide Tablets 1 mg and 2 mg, which is the generic version of the reference listed drug (RLD) Orap.
Notably, U.S. annual sales for Pimozide Tablets total approximately $3.1 million, as per the February 2026 moving annual total IQVIA data.
"We are excited to bring limited competition products to market and continue to provide generic alternatives to our customers and patients," commented Nikhil Lalwani, President and Chief Executive Officer of ANI.
In the pre-market hours, ANIP is trading at $82.38, up 1.80 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.